SCHEMBL3557745

SCHEMBL3557745

N#C/C(=C\c1ccc(-n2ccc(-c3ccccc3)n2)cc1)C(=O)c1ccco1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 6/20 0.39
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
PKM P14618 1/20 0.39
ATM Q13315 1/20 0.39
MAPT P10636 5/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 5/20 0.37
TAS2R14 Q9NYV8 1/20 0.37
PLIN1 O60240 1/20 0.36
PLIN5 Q00G26 1/20 0.36
ABHD5 Q8WTS1 1/20 0.36
MCL1 Q07820 1/20 0.36
HPGD P15428 2/20 0.36
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3557749 1.00 CYP2C9 (0.43) CYP2C9KMT2AKDM4EALDH1A1PKM
SCHEMBL3557131 0.85 CYP2C9 (0.43) CYP2C9KMT2AKDM4EALDH1A1PKM
SCHEMBL3557129 0.85 CYP2C9 (0.43) CYP2C9KMT2AKDM4EALDH1A1PKM
SCHEMBL3562516 0.78 KMT2A (0.39) KMT2AKDM4EALDH1A1PKMATM
SCHEMBL3562519 0.78 KMT2A (0.39) KMT2AKDM4EALDH1A1PKMATM
SCHEMBL3562071 0.73 CYP2C9 (0.43) CYP2C9KMT2AKDM4EALDH1A1PKM
SCHEMBL3562073 0.73 CYP2C9 (0.43) CYP2C9KMT2AKDM4EALDH1A1PKM
SCHEMBL3560131 0.73 ORAI1 (0.40) CYP2C9KMT2AKDM4EALDH1A1MAPT
SCHEMBL3557982 0.72 KMT2A (0.54) KMT2AKDM4EALDH1A1PKMATM
SCHEMBL3557978 0.72 KMT2A (0.54) KMT2AKDM4EALDH1A1PKMATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705029-B2 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2010-04-27 US disclosed
EP-1732900-A4 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP (US) 2007-12-12 EP disclosed
US-20070270478-A1 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-11-22 US disclosed
US-7202232-B2 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-04-10 US disclosed
EP-1732900-A2 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2006-12-20 EP disclosed
US-20050272699-A1 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. 2005-12-08 US disclosed
WO-2005091752-A2 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272699-A1 Acrylonitrile derivatives for inflammation and immune-related uses IL1B, IL6, TLR4 CYP2C9 1235/4885KMT2A 4809/4885KDM4E 4711/4885
US-20070270478-A1 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES IL1B, IL6, TLR4 CYP2C9 1235/4885KMT2A 4809/4885KDM4E 4711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.